CA3127494A1 - Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence - Google Patents

Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence Download PDF

Info

Publication number
CA3127494A1
CA3127494A1 CA3127494A CA3127494A CA3127494A1 CA 3127494 A1 CA3127494 A1 CA 3127494A1 CA 3127494 A CA3127494 A CA 3127494A CA 3127494 A CA3127494 A CA 3127494A CA 3127494 A1 CA3127494 A1 CA 3127494A1
Authority
CA
Canada
Prior art keywords
cytidine
deaminase
fusion protein
base editor
cytidine deaminase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127494A
Other languages
English (en)
French (fr)
Inventor
Nicole GAUDELLI
Yi Yu
Ian SLAYMAKER
Jason Michael GEHRKE
Seung-Joo Lee
David A. BORN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beam Therapeutics Inc
Original Assignee
Beam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beam Therapeutics Inc filed Critical Beam Therapeutics Inc
Publication of CA3127494A1 publication Critical patent/CA3127494A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA3127494A 2019-01-31 2020-01-31 Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence Pending CA3127494A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962799702P 2019-01-31 2019-01-31
US62/799,702 2019-01-31
US201962835456P 2019-04-17 2019-04-17
US62/835,456 2019-04-17
US201962941569P 2019-11-27 2019-11-27
US62/941,569 2019-11-27
PCT/US2020/016288 WO2020160517A1 (en) 2019-01-31 2020-01-31 Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence

Publications (1)

Publication Number Publication Date
CA3127494A1 true CA3127494A1 (en) 2020-08-06

Family

ID=71842357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127494A Pending CA3127494A1 (en) 2019-01-31 2020-01-31 Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence

Country Status (8)

Country Link
US (1) US20220136012A1 (cg-RX-API-DMAC7.html)
EP (1) EP3918077A4 (cg-RX-API-DMAC7.html)
JP (2) JP7600122B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210124280A (cg-RX-API-DMAC7.html)
CN (2) CN114072509B (cg-RX-API-DMAC7.html)
AU (1) AU2020216484A1 (cg-RX-API-DMAC7.html)
CA (1) CA3127494A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020160517A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343921A (zh) * 2022-07-05 2024-01-05 华东师范大学 胞嘧啶碱基编辑器及其应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4103705A4 (en) * 2020-02-14 2024-02-28 Ohio State Innovation Foundation Nucleobase editors and methods of use thereof
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
BR112023019539A2 (pt) * 2021-03-26 2023-12-05 Beam Therapeutics Inc Variantes de adenosina desaminase e usos das mesmas
EP4323501A1 (en) * 2021-04-16 2024-02-21 Beam Therapeutics Inc. Genetic modification of hepatocytes
WO2022261509A1 (en) * 2021-06-11 2022-12-15 The Broad Institute, Inc. Improved cytosine to guanine base editors
EP4396207A4 (en) * 2021-09-03 2025-07-16 Univ Chicago POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS
WO2023086953A1 (en) * 2021-11-11 2023-05-19 Beam Therapeutics Inc. Compositions and methods for the treatment of hereditary angioedema (hae)
CN114686456B (zh) * 2022-05-10 2023-02-17 中山大学 基于双分子脱氨酶互补的碱基编辑系统及其应用
EP4540378A1 (en) * 2022-06-20 2025-04-23 CRISPR Therapeutics AG Base editing proteins and uses thereof
US20260139238A1 (en) * 2022-10-19 2026-05-21 Dna Script Methods and products for removal of uracil containing polynucleotides
WO2024125313A1 (zh) * 2022-12-15 2024-06-20 中国科学院遗传与发育生物学研究所 一种碱基编辑器及其应用
CN120699942A (zh) * 2023-02-28 2025-09-26 锐正基因(苏州)有限公司 用于碱基编辑的脱氨酶
CN118871578A (zh) 2023-05-24 2024-10-29 锐正基因(苏州)有限公司 用于碱基编辑的脱氨酶及其变体
CN117210445A (zh) * 2023-08-29 2023-12-12 苏州湃芮生物科技有限公司 一种基于rna特异性脱氨酶突变体及其应用
CN120813698A (zh) * 2023-09-22 2025-10-17 北京大学现代农业研究院 改进的基因组编辑方法
CN122349566A (zh) * 2023-12-06 2026-07-07 北京齐禾生科生物科技有限公司 优化的qbe碱基编辑系统及其应用
WO2025202473A1 (en) * 2024-03-28 2025-10-02 Revvity Discovery Limited A nucleic acid deaminase, a base editor and uses thereof
WO2025240372A1 (en) * 2024-05-13 2025-11-20 Metagenomi, Inc. Compositions and methods for editing t cells
CN121087015A (zh) * 2025-11-03 2025-12-09 中国农业大学 编辑效率提高的Casδ变体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166984A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2017070632A2 (en) * 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
IL306092A (en) * 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3625342B1 (en) * 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
CA3063733A1 (en) * 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
WO2019084062A1 (en) * 2017-10-23 2019-05-02 The Broad Institute, Inc. SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION
KR102959497B1 (ko) * 2018-05-11 2026-05-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법
WO2019226953A1 (en) * 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
KR102894715B1 (ko) * 2018-08-03 2025-12-03 빔 테라퓨틱스, 인크. 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
KR20210116526A (ko) * 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343921A (zh) * 2022-07-05 2024-01-05 华东师范大学 胞嘧啶碱基编辑器及其应用

Also Published As

Publication number Publication date
JP7779988B2 (ja) 2025-12-03
JP2025041661A (ja) 2025-03-26
EP3918077A4 (en) 2023-03-29
US20220136012A1 (en) 2022-05-05
JP2022521460A (ja) 2022-04-08
AU2020216484A1 (en) 2021-07-29
WO2020160517A1 (en) 2020-08-06
CN114072509A (zh) 2022-02-18
KR20210124280A (ko) 2021-10-14
CN114072509B (zh) 2025-04-15
CN120400115A (zh) 2025-08-01
EP3918077A1 (en) 2021-12-08
JP7600122B2 (ja) 2024-12-16

Similar Documents

Publication Publication Date Title
CA3128755C (en) Compositions and methods for treating hemoglobinopathies
JP7531923B2 (ja) 核酸塩基編集因子およびその使用
CA3128878A1 (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
US20230348883A1 (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
JP7657711B2 (ja) 核酸塩基編集システムを送達するための組成物および方法
US12454694B2 (en) Compositions and methods for improving base editing
CA3108281A1 (en) Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
CA3140093A1 (en) Methods of editing a single nucleotide polymorphism using programmable base editor systems
CA3128886A1 (en) Compositions and methods for treating glycogen storage disease type 1a
CA3153624A1 (en) Nucleobase editors and methods of using same
CN120400115A (zh) 脱氨反应脱靶减低的核碱基编辑器和使用其修饰核碱基靶序列的方法
EP3486318B1 (en) Nuclease profiling system
CA3208612A1 (en) Recombinant rabies viruses for gene therapy
CA3152861A1 (en) Compositions and methods for editing a mutation to permit transcription or expression
CA3100019A1 (en) Methods of substituting pathogenic amino acids using programmable base editor systems
WO2020168075A9 (en) Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
US20240158775A1 (en) Adenosine deaminase variants and uses thereof
CA3006781A1 (en) Methods and compositions for the making and using of guide nucleic acids
CA3139324A1 (en) Compositions and methods for treating hepatitis b
CA3219767A1 (en) Compositions and methods for treating transthyretin amyloidosis
US20230270840A1 (en) Viral guide rna delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220316

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250417

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250417

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715